Dec 03, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
Dec 02, 2019
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH
Nov 20, 2019
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
Nov 06, 2019
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
Oct 18, 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Sep 06, 2019
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Aug 23, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Jun 25, 2019
Global Myelofibrosis Market 2017-2018 & 2019-2026: Celgene's $1.1bn Impact Buy is First of More Deals to Come in 2018 and Beyond
Jun 19, 2019
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Jun 05, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
Jun 04, 2019
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
Jan 24, 2019
Global Rheumatoid Arthritis Therapeutics Market 2019-2025: Preference for Combination Therapies Growing Demand for JAK Inhibitors, Anti-ACPAs for Clinical Diagnosis, FDA Approval of Auto-Injector
Dec 03, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
Nov 27, 2018
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
Nov 20, 2018
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
Oct 22, 2018
Reistone Biopharma, a new Chinese biotech company ready to initiate its Ulcerative Colitis phase II clinical trial globally
Aug 22, 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Aug 20, 2018
US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
Jun 15, 2018
JAK Inhibitors Associated with Aggressive Lymphoma